Egypt's Prime Minister Mostafa Madbouly chaired a high-level meeting on Sunday to review the availability of pharmaceutical products and active raw materials in the domestic market. The session, attended by ministers and officials, emphasized ensuring adequate strategic drug reserves and monitoring supply chains while advancing localization efforts. A detailed report confirmed sufficient inventories to meet local demand.
Egypt's Prime Minister Mostafa Madbouly chaired a high-level meeting on Sunday, attended by relevant ministers and officials, to assess pharmaceutical products and active raw materials in the domestic market.
Madbouly stressed the government's commitment to ongoing oversight of strategic medicine stocks, highlighting the need to bolster local manufacturing capabilities for healthcare security. The review encompassed critical supplies such as radiology materials, blood banks, vascular and general surgery items, cardiology catheters, dialysis, ophthalmology, laboratory services, and specialized procedures including cardiac, thoracic, and neurosurgery.
A presented report indicated that Ministry of Health inventories are sufficient to cover local demand for a reassuring period. It confirmed availability of essential medicines for cardiovascular conditions, anticoagulants, emergencies, respiratory and gastrointestinal therapies, seasonal colds, women's health, diabetes and endocrine disorders, analgesics, tuberculosis, vitamins, oncology, immunology, psychiatric and dermatological treatments, anaesthetics, antimicrobials, blood proteins, and anti-allergy drugs.
Egypt's pharmaceutical market grew 9% in 2025, with production reaching 3.9 billion units from 3.5 billion in 2024. Officials are monitoring raw material stocks and tracking imports daily amid geopolitical tensions, with stable import levels noted. The Egyptian Unified Procurement Authority reported adequate reserves, reaffirming efforts to secure supplies and localize production.